Medical technologies specialist Globus Medical (NYSE:GMED) reported impressive results for the fourth quarter of 2024 on ...

GMED earnings call for the period ending December 31, 2024.

Globus Medical started 2025 on a solid note, but a deal for loss-making Nevro creates some discomfort among investors. Read ...

Globus Medical (NYSE:GMED) shares dipped today despite fourth-quarter results that came in ahead of the consensus forecast.

Wells Fargo analyst Vik Chopra lowered the firm’s price target on Globus Medical (GMED) to $93 from $95 and keeps an Overweight rating on the ...

BTIG analyst Ryan Zimmerman raised the firm’s price target on Globus Medical (GMED) to $94 from $91 and keeps a Buy rating on the shares after ...

Globus Medical Inc (GMED) reports a 61% annual revenue increase and outlines strategic plans following the Nevro acquisition.

Acquisition of Nevro Corp. In a strategic move announced in early 2025, Globus Medical agreed to acquire Nevro Corp. for $250 million. This acquisition is seen as a calculated step to enhance ...

Acquisition of Nevro Corp. In a strategic move announced in early 2025, Globus Medical agreed to acquire Nevro Corp. for $250 million. This acquisition is seen as a calculated step to enhance Globus ...

On February 7, 2025, Nevro Corp was acquired by Globus Medical (NYSE:GMED) in an all-cash transaction valuing NVRO at $5.85 per share, representing a total equity value of approximately $250 million.